Why uniQure N.V. Stock Is Hopping Today
Shares of the gene therapy company uniQure N.V. (NASDAQ: QURE) rose by as much as 27% in early-morning trading today on over 27 times the average volume. uniQure's stock is responding positively to the unexpected advancement of its experimental hemophilia B treatment, AMT-061, into a late-stage study.
Specifically, uniQure said that it plans to initiate a pivotal-stage trial for AMT-061 in 2018 for patients with severe and moderately severe hemophilia B after consulting with both American and European regulatory authorities on the matter.
Image source: Getty Images.
Source: Fool.com
Uniqure B.V. Aktie
7,21 €
1,93 %
Gleichstand bei Uniqure B.V.: 1 Buy-Einschätzungen entsprechen 2 Sell-Einschätzungen.
Obwohl das Kursziel für Uniqure B.V. bei 11 € liegt, was über dem aktuellen Kurs von 7.21 € ist, zeigt sich ein Potenzial von 52.52%.
